On January 23, 2020 Cancer Research Center of Toulouse reported that Immunotherapies are imposing themselves as a revolution in cancer treatment, giving hope to many previously incurable patients (Press release, Cancer Research Center of Toulouse, JAN 23, 2020, View Source [SID1234553456]). They aim to restore the natural defences mounted by the body against cancerous cells, such as lymphocytes, which are often disarmed by the tumour. Despite the promising potential, around 30% of patients do not benefit at all from immunotherapy. Better characterising the inter-cellular interactions in the tumour microenvironment will be key to propose new kinds of immunotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LungPredict involves performing a deep molecular characterisation of lung cancer patients at diagnosis, to offer them personalised therapeutic approaches. The pilot phase (2019) consisted in developing logistic, experimental and bioinformatic protocols, assessing the feasibility of the full project.

The plan is to produce transcriptomics, targeted sequencing and high-content imaging on tumour samples for a few hundred patients. Blood is also being collected for future analyses and all data is linked to patients’ clinical records.

As part of this alliance between the company, researchers and clinicians, more similar projects will be launched in the future to exploit an integrative approach to achieve better personalized treatments for other cancers as well.